SmithRx to Offer Adalimumab Biosimilar Yusimry at 90% Discou

The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost of the reference product, Humira.

Related Keywords

United States , America , Josztl Pbms , Katy Wong , Chris Slavinsky , Jake Frenz , Mark Cuban , Denny Lanfear , Coherus Biosciences , Amgen , Mark Cuban Cost Plus Drug Company , Cigna , Cost Plus Drugs , Cost Plus Drug , United States December , Cigna Pharmacy , Adalimumab , Humira , Yusimry , Pharmacy Benefit Manager , Cpbm ,